Weekly Spotlight - 31.10.24

In the News

New Insights into mGluR5's Role in Niemann-Pick Type C Disease

The study reveals that enhanced mGluR5 activity in Niemann-Pick type C disease leads to psychiatric issues. Using a mouse model, researchers found that mGluR5 accumulates intracellularly, affecting synaptic function. Treatment with an mGluR5 antagonist improved psychiatric symptoms, offering hope for new therapeutic strategies.

Virginia Family's Advocacy Secures FDA Approval for Critical Drug

A Virginia family's advocacy led to FDA approval of drugs for Niemann-Pick Disease type C, offering hope for 9-year-old Abby Alvey. Her family testified to secure the drugs, which have shown positive effects. They continue to raise awareness and aim for a cure through their nonprofit, Abby Strong.

Tau217 Levels Rise in Niemann-Pick Disease Type C

The study reveals that plasma phosphorylated-tau217 (p-tau217) levels are elevated in Niemann-Pick disease type C (NPC), similar to Alzheimer's disease. This biomarker correlates with disease progression, offering hope for better monitoring and understanding of NPC. The findings highlight p-tau217's potential as a valuable diagnostic tool.

Niemann-Pick Diseases: Genetic Insights and Therapeutic Advances

Niemann-Pick diseases are rare genetic disorders causing lipid accumulation in cells, primarily affecting children. This article explores their genetic basis, symptoms, and diagnostic methods. It highlights therapeutic strategies, offering hope for better management and improved quality of life for affected individuals and their families.

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!